All-Female Top Management at GSK
26th September 2022
GSK plc today announced that Julie Brown, currently Chief Operating and Financial Officer at Burberry Group plc will replace current CFO Iain Mackay, who is to retire in May 2023.
Jonathan Symonds, Chair, GSK said: “We are delighted that Julie will join the Board as Iain’s successor. She is a CFO of exceptional calibre and experience and I look forward to the contribution she will make.”
Julie will join GSK in April 2023 and will work with Iain to transition responsibilities, taking responsibility as CFO and as an Executive Director of GSK on 1 May 2023.
She is a highly respected CFO with extensive experience in the biopharma and medtech sectors, having previously worked at AstraZeneca plc and Smith & Nephew plc; and as a non-executive director and Audit Chair of Roche Holding AG. It is therefore not surprising that her base salary is set at c915k stg with a similar annual bonus figure and other benefits included.
Emma Walmsley, Chief Executive Officer, GSK, said: “I want to thank Iain for all he’s done for GSK, and for his leadership and support to our people. He has played a very significant role to help deliver the reshaping of GSK and to improve our operating and financial performance. I am absolutely delighted that Julie will be joining the leadership team as his successor. Julie is a highly experienced CFO with a tremendous understanding of the biopharma sector.
We also share a strong passion for people development, diversity, inclusion and sustainability.
I am looking forward to working together to deliver progress for patients, shareholders and our people.”
According to Reuters with ‘Emma Walmsley as GSK’s chief executive officer, Brown’s appointment also creates a rare, all-female top management at a blue-chip (.FTSE) British company and a global pharma major’.
Watch this space!